|
|
||
Pipeline 4 : Enhancing Host Expression Day 1
Although most scientists would argue that the science of protein expression is a mature one, there still exist many issues with yields, glycosylation, folding, inclusion bodies, and so on. There is still much that can be learned to overcome these challenges. New hosts are emerging that will provide solutions to these ongoing problems. In addition, new methods and technologies continue to provide improved yield and stability of proteins in the existing hosts. Cambridge Healthtech Institute’s 13th Annual “Enhancing Host Expression” (formerly “Protein Expression”) conference will present the cutting-edge methods and technologies that improve the outcomes in existing host systems, as well as new and novel hosts that will become the tools for the 21st Century protein expression scientist. Monday, January 11 7:30 am - 8:45 am Registration and Morning Coffee
IMPROVING EXPRESSION FROM THE BEGINNING 8:45 Chairperson’s Opening Remarks Dominic Esposito, Ph.D., Principal Scientist, Protein Expression Laboratory, SAIC-Frederick, Inc. 9:00 KEYNOTE PRESENTATION A Review of High Throughput Protein Production in Drug Discovery: Lessons Learned Ian Hunt, Ph.D., Protein Structure Unit, Centre for Proteomic Chemistry, Novartis Institutes for BioMedical Research The presentation will review some of the technologies and innovations that have been developed to accelerate the generation of recombinant proteins for the support of early drug discovery (HTS, biophysics & structural biology) within the pharmaceutical environment and will include some tricks of the trade and a look ahead at the future of protein production. 9:50 General and Adaptable High-Throughput Approaches for the Optimization of Protein Expression Robert Speight, Ph.D., Operations Director, Biotechnology, Ingenza Ltd. A novel screening system has been developed and demonstrated that allows for the high-throughput detection of genetic variants that exhibit increased expression levels. The system is highly tunable and versatile and relies on the fusion of the gene of interest to a reporter gene encoding an oxidase. The system is built on many years of experience of screening for oxidase activity and has been fully validated and used to identify specific codon optimized sequences from large libraries of variants. 10:20 Networking Coffee Break 10:45 Auditioning of CHO Host Cell Lines Using the Artificial Chromosome Expression (ACE) Technology Malcolm L. Kennard, Ph.D., Kennard Biologic Consultants The ACE System, based on targeted transfection through pre-engineered artificial chromosomes, was investigated as a technique to audition host cell lines. Clonal cell lines were generated from three CHO host cell lines (CHOK1SV, CHO-S and DG44) that had identical artificial chromosomes containing gene copies of a human monoclonal IgG1 antibody. The resulting large differences in antibody expression between the different CHO host cells were shown to be due to cell phenotype rather than genetic factors. 11:15 Anti-Apoptotic Factors Improve Productivity of Monoclonal Antibodies from CHO Cells Mark Levenstein, Ph.D., Scientific Director, Biochemistry, CDI Bioscience In batch bioreactors overpopulation, nutrient depletion, and waste accumulation create a hostile environment for in vitro cell culture, triggering apoptosis, cutting short the productive phase of a recombinant therapeutic production run. With access to more ATP individual cells produce more protein. An expanded endoplasmic reticulum facilitates synthesis and secretion of protein products into the culture medium. In CHO cells the combined effects of p16 and p21 result in a three-fold increase in protein productivity as measured in picograms per cell per day. 11:45 Using the Pichia pastoris Genome(s) to Optimize Secreted Heterologous Protein Expression Thomas Chappell, Ph.D., Founder and Principal Scientist, BioGrammatics, Inc. The recent publication of genome sequences from several Pichia pastoris strains and/or closely related species has provided the basis for optimization of protein expression in this widely used host system. Our focus has been on generating a panel of reporter strains where the stress response to a specific heterologous protein can be quantified in different genetic backgrounds. This output can then be used to choose specfic expression partners to optimize protein folding and transit through the secretory pathway. 12:15 pm Close of Morning Session Sponsored by Focus on Your Freedom to Innovate: How Blue Sky’s BioProducts & Collaborative Product Development Alliances Can Help You Scott Gridley, Ph.D., Head of Product Development, Blue Sky Biotech 1:00 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own
EXPRESSION SYSTEM ENGINEERING 2:00 Chairperson’s Remarks 2:05 Designing of Pichia pastoris Fermentation Process for Expressing Unstable Proteins Sanjay Tiwari, Senior Scientific Manager, Research & Development, Biocon Limited Optimization of concentration of salts in the Pichia fermentation medium as well as complex nutrient sources has a major impact upon product quality in terms of degradation products, glycoforms, and overall productivity. The salt complexes dramatically influence the availability of ions and hence the productivity in terms of grams per litre of broth per hour. Design of the limiting parameters of the fed batch process parameters is the key to ensure smooth scalability by a factor of about 1000. 2:35 High-Throughput Protein Expression Using Cell-Free Systems Deb K. Chatterjee, Ph.D., Protein Expression Laboratory, SAIC-Frederick, Inc., National Cancer Institute Traditionally, the cell-free transcription/translation system has been used mainly for analytical purpose to characterize gene products. However, recent developments made cell-free protein synthesis as an alternative to cell-based synthesis and solved many of problems associated with in vivo systems. Furthermore, this technology is readily amenable to automation. We will present examples for expressing recombinant proteins with high yield (mg quantities) using highly active S30 extract in home-made inexpensive dialysis method in a high-throughput manner. 3:05 Hijacking the Regulated Secretory Pathway of Tetrahymena for High-Level Expression of Recombinant Proteins Theodore Clark, Ph.D., Associate Professor, Microbiology and Immunology, Cornell University The common pondwater ciliate, Tetrahymena thermophila, stores large amounts of protein in several thousand dense core secretory granules that can be triggered to discharge their contents to the extracellular space at will. The material secreted from cells takes the form of a proteinaceous gel that can be readily harvested by low speed centrifugation. When combined with ribosomal DNA vectors that replicate to ~18,000 copies per cell as palindromic minichromosmes, the regulated secretory pathway of Tetrahymena can be harnessed for high-level expression and streamlined purification of recombinant proteins in a process that is tantamount to affinity chromatography in vivo. 3:35 Pfēnex Expression TechnologyTM: The New Standard for Protein Expression
3:50 Networking Refreshment Break 4:15 A Cell-Free Translation System for Producing Complex Disulfide Bonded Proteins at the Multiliter Scale Christopher Murray, Ph.D., Senior Director, Research, Sutro Biopharma Sutro’s OCFS system produces complex eukaryotic proteins such as cytokines and Fab antibody fragments up to 100 L scale at yields approaching 1 g/L. The open system allows us to model and rapidly optimize the system without the requirement of tuning more complex cellular networks required to maintain cell viability. The linear scalability of the system means that engineered proteins identified in high-throughput screens and selections can be immediately scaled for production of gram to kilogram quantities, thus avoiding the delays and challenges of conventional mammalian cell line development. 4:45 Harnessing Proteomics to Engineer a Better Protein Expression System Stephen P. Chambers, Ph.D., Vice President, Protein Production, AbPro We utilize proteomic-wide access to the whole of the human genome to assist in the selection and improvement of protein expression hosts. We will be rolling out the 3,000 proteins encoded by the secreted genome, to be followed by the 3,000 proteins of the druggable genome. This tool will allow protein researchers to more efficiently produce their proteins of interest. 5:15 Micro-Algae as a Platform for the Production of Therapeutic Proteins Steve P. Mayfield, Ph.D., Associate Dean, Department of Cell Biology, The Skaggs Institute for Chemical Biology, The Scripps Research Institute 5:45 Welcoming Reception in the Exhibit Hall 7:00 Close of Day
Links to Companion Meetings
|
Choose your language
Join our LinkedIn Group
|
|
Cambridge Healthtech Institute Global Information, Inc. - International Marketing Partner of Cambridge Healthtech Institute.